Blocking PRDX6 Strips Cancer Cells of Their Ferroptosis Shield and Shrinks Tumors in Mice

Ferroptosis, a form of cell death caused by runaway lipid peroxidation, is an attractive anticancer strategy. Many tumors resist it, however, which limits how well ferroptosis-inducing drugs could work. Understanding how cancer cells defend themselves is a prerequisite for getting around that resistance.

This study looked at peroxiredoxin 6 (PRDX6), an enzyme with phospholipase A2 activity that converts peroxidized phospholipids into lysophospholipids and oxidized fatty acids. The team asked whether PRDX6 influences GPX4, the central enzyme that detoxifies lipid peroxides. Using targeted structural mutations and biochemical analyses, they examined how the two proteins interact and what this does to GPX4's location and function.

PRDX6 binds GPX4 through a disulfide bond involving cysteine 47. This interaction helps GPX4 move to membranes and increases its production of hydroxy fatty acids, strengthening protection against ferroptosis. Inhibiting PRDX6 alongside ferroptosis inducers raised lipid peroxidation and suppressed tumor growth in mouse models of liver and ovarian cancer, including patient-derived models. In human data, high PRDX6 expression was associated with shorter progression-free survival in multiple cancer types.

These findings describe a previously unrecognized layer of ferroptosis defense and suggest that pairing PRDX6 inhibition with ferroptosis inducers could overcome resistance. For longevity and oncology audiences, the work also highlights how lipid peroxidation and redox enzymes shape cell fate.

Several caveats apply. This summary draws on the abstract only, so detailed methods, dosing, and safety data were not reviewed. The evidence is preclinical, mostly from cell and mouse models. Whether PRDX6 inhibition would be tolerable and effective in people, and how it might affect healthy tissues that depend on ferroptosis defense, remains unknown. The survival association is correlative.